POXIL CV 100 TABLETS

Indications

• Respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections
• Otitis media

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Cefpodoxime exerts its bactericidal effect by inhibiting cell wall synthesis. The active metabolite binds preferentially to penicillin-binding protein 3, which leads to the inhibition of peptidoglycan production, the main component of bacterial cell walls. This mechanism is particularly effective against various Gram-positive and Gram-negative bacteria, enhancing its therapeutic utility in treating infections.

Pharmacodynamics

Cefpodoxime demonstrates effectiveness against most Gram-positive and Gram-negative bacteria, with notable exceptions including Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Its ability to remain stable in the presence of beta-lactamase enzymes allows it to target bacteria that are otherwise resistant to beta-lactam antibiotics.

Pharmacokinetics

Cefpodoxime is well absorbed after oral administration, with its bioavailability enhanced by the presence of food. It is distributed widely in body tissues and fluids, with a significant volume of distribution. Cefpodoxime is primarily eliminated via renal excretion, with a half-life sufficient for twice-daily dosing in most cases. The active metabolite contributes to the antimicrobial activity and is also eliminated through renal pathways.

Adverse effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Allergic reactions
• Elevated liver enzymes

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of superinfection
• Assess for history of penicillin allergy

Pregnancy

Cefpodoxime is classified as pregnancy category B. Animal studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if clearly needed.

Breast-feeding

Cefpodoxime is excreted in breast milk. Caution is advised when administering to nursing mothers, as adverse effects on the infant are possible.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Oral suspension

Indications

• Bacterial infections caused by beta-lactamase producing organisms
• Community-acquired pneumonia
• Respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections

Dosage

Children: Paediatric dosing of clavulanate should be determined based on the specific indication and the formulation used. Refer to the BNF for

Adults: The usual adult dose of clavulanate varies depending on the specific antibiotic it is combined with, generally ranging from 125 mg to 250 mg, taken every 8 hours when combined with amoxicillin.

Mechanism of action

Clavulanate works by irreversibly binding to the active site of beta-lactamase enzymes. By inhibiting these enzymes, clavulanate protects beta-lactam antibiotics from degradation, allowing them to exert their antibacterial effects effectively. This mechanism enhances the spectrum of activity of the co-administered antibiotic, thereby improving clinical outcomes in infections caused by beta-lactamase producing organisms.

Pharmacodynamics

Clavulanate exhibits a time-dependent antibacterial effect, characterized by its ability to maintain effective concentrations against beta-lactamase producing bacteria. Its pharmacodynamic properties are mainly influenced by its interaction with beta-lactam antibiotics, enhancing their efficacy in treating infections. The overall effect is a synergistic relationship that increases the potency of the antibiotic treatment.

Pharmacokinetics

Clavulanate is usually administered orally or parenterally, and it is rapidly absorbed from the gastrointestinal tract. It reaches peak plasma concentrations within 1 to 2 hours after administration. The drug is widely distributed in body tissues, with a volume of distribution indicative of good tissue penetration. Clavulanate undergoes hepatic metabolism, primarily by conjugation, and is excreted largely in the urine as metabolites. The elimination half-life is approximately 1 hour, necessitating frequent dosing for optimal therapeutic effect.

Contra-indications

• Hypersensitivity to clavulanate or any component of the formulation
• History of jaundice or hepatic impairment related to previous use of beta-lactam antibiotics

Adverse effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Hepatic dysfunction
• Allergic reactions

Interactions

• Probenecid may increase concentrations of clavulanate
• Anticoagulants may have altered effects due to changes in gut flora

Precautions

• Monitor liver function during prolonged therapy
• Use cautiously in patients with renal impairment
• Assess for history of allergy to penicillins or cephalosporins

Pregnancy

Clavulanate is classified as category B. Animal studies have not shown teratogenic effects, but adequate and well-controlled studies in pregnant women are lacking.

Breast-feeding

Clavulanate is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Formulations

• Clavulanate potassium 125 mg/5 mL
• Clavulanate potassium 250 mg/5 mL

Indications

• Pediatric dosing adjustments
• Intravenous therapy
• Intramuscular injections
• Topical applications
• Oral medications for easier swallowing

Dosage

Children: Refer to the BNF for Children for appropriate dosing adjustments based on age and weight.

Adults: Refer to specific drug guidelines for appropriate dilution and dosage based on the active ingredient.

Mechanism of action

The mechanism of action of a diluted drug depends on the specific active ingredient within the solution. Generally, when a drug is diluted, its pharmacological effects are proportional to its concentration. The active molecules interact with specific receptors or enzymes in the body, leading to a desired therapeutic effect. For example, an analgesic diluted for oral administration will still bind to pain receptors, albeit at a lower intensity compared to its concentrated form.

Pharmacodynamics

Pharmacodynamics refers to the relationship between drug concentration and its effect on the body. In diluted solutions, the pharmacodynamic properties of the active ingredient remain intact, though the therapeutic effect may be reduced due to the lower concentration. The efficacy of the drug is influenced by factors such as receptor affinity, intrinsic activity, and the presence of other substances in the formulation.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of drugs. For diluted drugs, absorption can be affected by the dilution medium, which may enhance or delay the onset of action. Distribution is generally influenced by the volume of distribution of the active ingredient. Metabolism occurs primarily in the liver, where the drug is biotransformed, and excretion is typically via the kidneys. The pharmacokinetic profile may differ based on the dilution level and formulation.

Pregnancy

Consult a healthcare provider, as the effects of diluted preparations can vary depending on the active ingredient.

Breast-feeding

Consult a healthcare provider, as the safety of diluted preparations during breastfeeding can depend on the active ingredient.

Storage

Store in a cool, dry place away from direct sunlight. Ensure that the specific active ingredient's storage requirements are followed.

Indications

• Major depressive disorder
• Generalized anxiety disorder
• Obsessive-compulsive disorder
• Panic disorder
• Post-traumatic stress disorder

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations, as pediatric dosing may differ significantly from adult dosing.

Adults: Refer to the specific prescribing information for dosing guidance as it may vary based on individual patient factors and clinical judgment.

Mechanism of action

Proxetil functions as a selective serotonin reuptake inhibitor (SSRI), which means it inhibits the reuptake of serotonin (5-HT) in the presynaptic neuron. By blocking the serotonin transporter (SERT), it increases the availability of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission. This mechanism is believed to contribute to its antidepressant effects.

Pharmacodynamics

The pharmacodynamics of proxetil involve the modulation of serotonin levels in the central nervous system. The increase in serotonin availability leads to improved mood, reduction in anxiety, and overall enhancement of emotional well-being. The onset of therapeutic effects may take several weeks, and the drug is generally well tolerated, with common side effects including gastrointestinal disturbances and changes in sexual function.

Pharmacokinetics

Proxetil is absorbed rapidly after oral administration, with peak plasma concentrations occurring within several hours. It undergoes extensive first-pass metabolism, primarily in the liver, which affects its bioavailability. The drug is metabolized by cytochrome P450 enzymes, and its elimination half-life is generally around 24 hours, allowing for once-daily dosing. It is excreted mainly in urine, with a small amount excreted as unchanged drug.

Contra-indications

• Hypersensitivity to proxetil or any of its components
• Severe hepatic impairment
• Concurrent use with monoamine oxidase inhibitors (MAOIs)

Adverse effects

• Nausea
• Diarrhea
• Dizziness
• Somnolence
• Dry mouth
• Insomnia
• Sexual dysfunction

Interactions

• Caution when used with other central nervous system depressants
• May increase the effects of anticoagulants
• Potential interaction with other serotonergic drugs, increasing the risk of serotonin syndrome

Precautions

• Use with caution in patients with a history of seizures
• Monitor for worsening of depression or emergence of suicidal thoughts
• Consider potential for withdrawal symptoms upon discontinuation

Pregnancy

Proxetil should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult clinical guidelines for further information.

Breast-feeding

Proxetil is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Oral solution

Mechanism of action

Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls.

Pharmacodynamics

Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except <i>Pseudomonas aeruginosa</i>, <i>Enterococcus</i>, and <i>Bacteroides fragilis</i>.